Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The key is quality and consistency
It helps in giving energy to the body
Kristi Kratovil, clinical lead for obesity medicine at Sentara Health
Phase 2: Market Creation at Scale Novo Nordisk didnt just innovateit scaled demand aggressively: Positioned GLP-1 as a dual-solution drug (diabetes + weight loss) Expanded into non-diabetic populations seeking weight management Invested heavily in manufacturing and global supply chains Built direct-to-consumer channels to improve access By 2025: GLP-1 drugs became the primary growth driver for the company Novo Nordisk held a dominant share in the GLP-1 market Demand surged globally, driven by rising obesity and diabetes rates The broader GLP-1 market is now expected to grow at ~14% CAGR, driven by lifestyle diseases and expanding use cases
